Focusing mainly on megakaryoblastic leukemias, the EuroFLOW has included the megakaryocytic/platelet markers CD61, CD41 and CD42a in the AML/MDS panel, albeit not considering them beneficial for the evaluation of suspected MDS (76). This evidence concerns the gene GP9 and acute myeloid leukemia.